Pharming Group (OTCMKTS:PHGUF) Sees Large Volume Increase – Time to Buy?

Shares of Pharming Group NV (OTCMKTS:PHGUF) saw unusually-strong trading volume on Tuesday . Approximately 20,000 shares changed hands during trading, an increase of 203% from the previous session’s volume of 6,591 shares.The stock last traded at $1.24 and had previously closed at $1.6350.

Pharming Group Stock Performance

The company has a debt-to-equity ratio of 0.39, a quick ratio of 2.03 and a current ratio of 2.59. The company has a market cap of $832.13 million, a PE ratio of 62.03 and a beta of 0.55. The company’s 50 day moving average price is $1.58 and its 200-day moving average price is $1.65.

Pharming Group (OTCMKTS:PHGUF) last posted its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.01) EPS for the quarter. Pharming Group had a net margin of 3.30% and a return on equity of 4.68%. The firm had revenue of $72.45 million during the quarter, compared to analysts’ expectations of $92.06 million.

Pharming Group Company Profile

Pharming Group NV is a Netherlands-based biopharmaceutical company specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988 and headquartered in Leiden, the company leverages transgenic technology to produce recombinant proteins, with its flagship product RUCONEST (recombinant C1 esterase inhibitor) indicated for the treatment of acute hereditary angioedema (HAE) attacks. RUCONEST is approved and marketed in the United States, Europe and several other territories through partnerships with leading specialty pharmaceutical companies.

Beyond RUCONEST, Pharming maintains a diversified pipeline targeting unmet needs in rare and ultra-rare disorders.